Genscript Biotech Revenue Surges 27.3% in H1 2026 as AI-Driven Drug Discovery Demand Lifts Margins

The Quick Take

• Genscript Biotech Corp (GNNSF) reported H1 2026 revenue surging 27.3% to $404.2 million, driven by strong demand for AI-assisted drug discovery services through its life-science services (LSG) division.
• LSG operating profit doubled in H1 2026, and management raised full-year guidance to 25-30% growth — a significant upward revision that signals sustained momentum beyond the first half.
• L1 Group (ASX:L1G) separately posted record FY26 results with 49% revenue growth and EBITDA doubling to $287.4M, reflecting strong fund performance and raised cost-synergy targets after acquisitions.

Genscript Biotech's H1 2026 performance represents one of the stronger print-and-raise narratives in the life-science services sector this earnings season. The 27.3% revenue growth to $404.2 million reflects genuine demand acceleration for AI-enhanced biological research services — a market where Genscript's scale in gene synthesis, cell therapy services, and drug discovery platforms positions it as a primary beneficiary of pharmaceutical companies' AI-assisted R&D buildout. The doubling of LSG operating profit is particularly significant, as operating leverage at scale validates the thesis that Genscript's fixed-cost research infrastructure can absorb rapid revenue growth without proportional cost increases.

The guidance raise to 25-30% full-year growth sets a high bar for H2 2026 delivery, implying that either H2 has already shown strong early momentum or management has exceptional visibility into contract backlog. Genscript's US listing (GNNSF) and primary Hong Kong listing give it exposure to both US institutional capital and Asian growth investors, though the company's operational headquarters in China introduces regulatory and geopolitical risk that some US investors discount. The AI-drug-discovery demand cycle underpinning Genscript's growth shows no near-term signs of abating, with major pharma and biotech companies continuing to invest heavily in accelerated compound screening and synthesis capabilities.

L1 Group's record FY26 earnings (49% revenue growth, EBITDA to $287.4M) represent a parallel success story in the Australian asset management sector. L1 Capital, the underlying fund manager, has built a strong track record in long/short equity strategies, and the FY26 result reflects both strong fund performance (driving performance fees) and the operational leverage inherent in asset management businesses. The raised cost-synergy targets signal management confidence in the post-acquisition integration runway. While L1 Group and Genscript operate in entirely different sectors, the clustering of their earnings into one market theme reflects the concurrent earnings season dynamics of August 2026.

Synthesized from 2 sources.